Table 2 ORR across tumor type and individual biomarker result
From: Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Disease | Test | PD-L1 result | Responders | Non-responders | Total | ORR |
|---|---|---|---|---|---|---|
Melanoma | IHC TPS | ≥1% | 10 | 8 | 18 | 55.60% |
< 1% | 22 | 36 | 58 | 37.90% | ||
RNA-seq | High | 8 | 3 | 11 | 72.70% | |
Moderate & low | 24 | 41 | 65 | 46.20% | ||
NSCLC | IHC TPS | ≥1% | 10 | 28 | 38 | 26.30% |
< 1% | 7 | 43 | 50 | 14.00% | ||
IHC TPS | ≥50% | 8 | 11 | 19 | 42.10% | |
< 50% | 9 | 60 | 69 | 13.00% | ||
RNA-seq | High | 10 | 25 | 35 | 28.60% | |
Moderate & low | 7 | 46 | 53 | 11.90% | ||
RCC | IHC TPS | ≥1% | 2 | 3 | 5 | 40.00% |
< 1% | 5 | 35 | 40 | 12.50% | ||
IHC ICS | ≥1% | 1 | 3 | 4 | 25.00% | |
< 1% | 6 | 35 | 41 | 14.60% | ||
RNA-seq | High | 3 | 6 | 9 | 33.30% | |
Moderate & low | 4 | 32 | 36 | 8.30% |